Micromet and Nycomed : Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases

June 24, 2008 - Micromet, Inc. (Nasdaq: MITI) and Nycomed announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203. Micromet received $775,000 (n 500,000) from Nycomed for the achievement of this milestone.
Under a 2007 agreement between the two companies, Micromet and Nycomed develop MT203, a fully human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases.

Preclinical studies support MT203's development for the treatment of rheumatoid arthritis and several other indications, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease... Micromet's Press Release -

Micromet : Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

April 23, 2008 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers. MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers... Micromet's Press Release -